EDIT - Editas Medicine Inc Long-Term Debt

Public company logo of Editas Medicine Inc (EDIT)

The price history of Editas Medicine, Inc. (EDIT) reflects the dynamics of a company developing innovative treatments through genetic code correction. The business's long-term advantage is based on low price sensitivity of demand for the correction of hereditary pathologies. The team consists of leading scientists attracted by stock options and pioneer status. The current metric stands at 0.06, while capital is replenished through patents as internal programs continue to develop.

Editas Medicine (EDIT) - Company Long-Term Debts from 07/04/2022 to 11/01/2026

Editas (EDIT) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price editasmedicine.com|EDIT - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Editas Medicine|EDIT - Enterprise Value
- book capitalization data:
Equity per Share Editas Medicine|EDIT - Book Capitalization|Market Capitalization to Book Value editasmedicine.com|EDIT - Cumulative Company Assets
- business debt structure and liquidity details:
Aggregate Debt to Capital Editas Medicine, Inc.|EDIT - Long-Term Debt to Capital|Short-Term Debt to Capital Editas Corp|EDIT - Company Debts|Debts to Net Assets Editas Medicine|EDIT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Editas Medicine|Quick Liquidity Indicator editasmedicine.com
- earnings and valuation multiples indicators:
EDIT - Net Profit
Analysis of all company metrics:EDIT editasmedicine.com
Product sample of Editas

Long-term debt measures the volume of obligations with a maturity of more than one year, reflecting the strategy of attracting external capital for expansion. Analyzing this metric allows for an assessment of financial stability and the risk of cash flow gaps. The trend in the organization's long-term financial debt indicates the business's reliance on borrowed funds. For Editas Medicine, Inc. (EDIT), this is critical, as the lack of revenue and high costs associated with CRISPR development necessitate constant external financing.

Competitor analysis for Editas Medicine, Inc.

Company Long-Term Debts Tempus Labs TEM|Qiagen - Company Long-Term Debts|Long-Term Debt Ionis Pharmaceuticals, Inc.|RGEN: Company Long-Term Debts|Company Long-Term Indebtedness RNA|CRSP (CRISPR Therapeutics AG) - Company Long-Term Debts|genedx.com (WGS) - Long-Term Debt Volume|Company Long-Term Liabilities RARE (Ultragenyx)|Amount of Long-Term Liabilities BEAM|Company Long-Term Debts SRPT (Sarepta Therapeutics Inc)|Company Long-Term Debts Twist Bioscience Corp TWST|TXG - Company Long-Term Debt|Long-Term Debt Volume intelliatx.com NTLA|STOK (Stoke Therapeutics, Inc.) - Company Long-Term Liabilities|BioLife Solutions Inc - Company Long-Term Loans and Borrowings|Company Long-Term Debt Wave Life Sciences Corp|Company Long-Term Liabilities Maze Therapeutics Corp (MAZE)|Company Long-Term Debts SION|PRME - Long-Term Debt|Company Long-Term Debts TSHA (Taysha Gene Therapies, Inc.)|QURE: Company Long-Term Indebtedness|MeiraGTx PLC - Company Long-Term Debts|Long-Term Debt Volume REGENXBIO Corp RGNX|SLDB: Company Long-Term Debts|Company Long-Term Liabilities ocugen.com|PACB (PacBio) - Company Long-Term Debts|Benitec Biopharma Inc (BNTC) - Long-Term Debt Volume|Company Long-Term Debt Design Pharma (DSGN)|Rocket Corp - Company Long-Term Indebtedness|Company Long-Term Debts FDMT (4D Molecular Therapeutics)|Lexeo Therapeutics Inc. (LXEO) - Long-Term Debt|KRRO: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings SLN (Silence Therapeutics PLC)|PRQR: Company Long-Term Debts|CDXS - Long-Term Debt Volume|Company Long-Term Debt Sangamo Therapeutics|Company Long-Term Indebtedness NAUT (Nautilus Biotechnology Inc)|Company Long-Term Debts MGX|Company Long-Term Liabilities Precision BioSciences Inc. DTIL|Generation Bio - Company Long-Term Liabilities|Long-Term Debt Volume Boundless Bio Inc (BOLD)|Exicure Corp - Company Long-Term Debts|Long-Term Debt Imunon, Inc.|PHIO: Company Long-Term Debts|Company Long-Term Indebtedness MBIO|RNAZ (TransCode Therapeutics Inc.) - Company Long-Term Debts|Bionano (BNGO) - Long-Term Debt Volume|Company Long-Term Liabilities APDN (Applied DNA Sciences)|Amount of Long-Term Liabilities BLUE|Company Long-Term Debts IPA (ImmunoPrecise Antibodies Ltd.)|OMGA: Company Long-Term Indebtedness|OMIC - Company Long-Term Debt|RGLS (Regulus) - Company Long-Term Indebtedness|SYRS: Company Long-Term Debts|telesisbio.com (TBIO) - Company Long-Term Debts|TCON (TRACON Pharmaceuticals, Inc.) - Company Long-Term Debts|Long-Term Debt Unity Biotechnology Inc. UBX